Yıl: 2013 Cilt: 41 Sayı: 7 Sayfa Aralığı: 633 - 637 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

A new hope in the treatment of coronary vasospasm: bosentan

Öz:
Akut koroner sendromların en önemli nedeni aterosklerozdur. Aterosklerotik plaklardan ve bunların çevresindeki endotelden endotelin ve serotonin gibi vazospazmı tetikleyici aracıların sentez edilip dolaşıma salgılandıkları bilinmektedir. Altmış sekiz yaşında erkek hasta son bir yıl içerisinde akut koroner sendrom tanısı ile dört kez hastaneye yatırıldı. En son Şubat 2012de göğüste yanma ve üst batında baskı tarzında ağrı ile merkezimiz acil servisine başvurdu. Troponin değerlerinde üç kattan fazla artış ve elektrokardiyografisinde iskemik değişiklikler saptanması üzerine koroner yoğun bakıma yatırıldı. Hastanın tedavisine kurul kararı ile endotelin reseptör antagonisti olan bosentan eklenmesine karar verildi. Hastanın kan ve hepatik göstergelerine göre bu tedaviye engel herhangi bir kontrendikasyon saptanmadı. Sosyal Güvenlik Kurumundan onay alındıktan sonra başlangıç dozu olarak günde iki kez 62.5 mg bosentan başlandı. Birinci aydan sonra günde iki kez 125 mg dozuna çıkıldı. Bosentan tedavisinin sekizinci ayı dolan hastanın anjina atağı veya akut koroner sendrom nedeniyle hastaneye yatışı olmadı.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Koroner vazospazm tedavisinde yeni bir umut: Bosentan

Öz:
Atherosclerosis is the most important cause of acute coronary syndromes. The mediators that trigger vaso- spasm, including endothelin and serotonin, are synthesized and secreted into circulation from atherosclerotic plaques and surrounding tissues. A 68-year-old man was hospitalized due to acute coronary syndrome four times in a one-year pe- riod. The patient presented to emergency service again with heartburn and a pressure-like pain in his upper abdomen in February 2012. He was admitted to the coronary care unit with the detection of a more than three-fold increase in tro- ponin values and ischemic changes on electrocardiography. By decision of the cardiology council, the endothelin recep- tor antagonist, bosentan was added to the treatment. There were no contraindications to this medication according to his blood and hepatic indicators. After confirmation of the Social Security Institution, bosentan was started as 62.5 mg twice a day. After the first month, the dose was increased to 125 mg b.i.d. As of completion of the eighth month of treatment with bosentan, the patient had not been hospitalized due to angina attack or acute coronary syndrome.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi
Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
  • 1. Waller BF. Nonatherosclerotic coronary heart disease. In: Fuster V, Alexander RW, O’Rourke R, Roberts R, King S, Wellens H, editors. Hurst’s the heart. 10th ed. New York: McGraw-Hill; 2001. p. 1162-8.
  • 2. Zeiher AM, Ihling C, Pistorius K, Schächinger V, Schaefer HE. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994;344:1405-6.
  • 3. Tzivoni D, Merin G, Milo S, Gotsman MS. Spasm of left main coronary artery. Br Heart J 1976;38:104-7.
  • 4. Murphy ES, Rösch J, Boicourt OW, Rahimtoola SH. Left main coronary artery spasm. A potential cause for angiographic misdiagnosis of severe coronary artery disease. Arch Intern Med 1976;136:350-1.
  • 5. Vermeltfoort IA, Raijmakers PG, Kamphuisen PW. Improved myocardial perfusion preceding clinical response on bosentan treatment for coronary vasospasm. Acta Cardiol 2009;64:415- 7.
  • 6. Krishnan U, Win W, Fisher M. First report of the successful use of bosentan in refractory vasospastic angina. Cardiology 2010;116:26-8.
  • 7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
  • 8. Lopez JA, Armstrong ML, Piegors DJ, Heistad DD. Vascular responses to endothelin-1 in atherosclerotic primates. Arteriosclerosis 1990;10:1113-8.
  • 9. Matsuyama K, Yasue H, Okumura K, Saito Y, Nakao K, Shirakami G, et al. Increased plasma level of endothelin-1-like immunoreactivity during coronary spasm in patients with coronary spastic angina. Am J Cardiol 1991;68:991-5.
  • 10. Dagassan PH, Clozel M, Breu V, Clozel JP. Role of endothelin in spontaneous phasic contraction of human coronary arteries. J Cardiovasc Pharmacol 1995;26:200-3.
APA GÜL İ, AYKAN A, GÖKDENİZ T, ÇELİK Ş (2013). A new hope in the treatment of coronary vasospasm: bosentan. , 633 - 637.
Chicago GÜL İlker,AYKAN Ahmet Çağrı,GÖKDENİZ Tayyar,ÇELİK Şükrü A new hope in the treatment of coronary vasospasm: bosentan. (2013): 633 - 637.
MLA GÜL İlker,AYKAN Ahmet Çağrı,GÖKDENİZ Tayyar,ÇELİK Şükrü A new hope in the treatment of coronary vasospasm: bosentan. , 2013, ss.633 - 637.
AMA GÜL İ,AYKAN A,GÖKDENİZ T,ÇELİK Ş A new hope in the treatment of coronary vasospasm: bosentan. . 2013; 633 - 637.
Vancouver GÜL İ,AYKAN A,GÖKDENİZ T,ÇELİK Ş A new hope in the treatment of coronary vasospasm: bosentan. . 2013; 633 - 637.
IEEE GÜL İ,AYKAN A,GÖKDENİZ T,ÇELİK Ş "A new hope in the treatment of coronary vasospasm: bosentan." , ss.633 - 637, 2013.
ISNAD GÜL, İlker vd. "A new hope in the treatment of coronary vasospasm: bosentan". (2013), 633-637.
APA GÜL İ, AYKAN A, GÖKDENİZ T, ÇELİK Ş (2013). A new hope in the treatment of coronary vasospasm: bosentan. Türk Kardiyoloji Derneği Arşivi, 41(7), 633 - 637.
Chicago GÜL İlker,AYKAN Ahmet Çağrı,GÖKDENİZ Tayyar,ÇELİK Şükrü A new hope in the treatment of coronary vasospasm: bosentan. Türk Kardiyoloji Derneği Arşivi 41, no.7 (2013): 633 - 637.
MLA GÜL İlker,AYKAN Ahmet Çağrı,GÖKDENİZ Tayyar,ÇELİK Şükrü A new hope in the treatment of coronary vasospasm: bosentan. Türk Kardiyoloji Derneği Arşivi, vol.41, no.7, 2013, ss.633 - 637.
AMA GÜL İ,AYKAN A,GÖKDENİZ T,ÇELİK Ş A new hope in the treatment of coronary vasospasm: bosentan. Türk Kardiyoloji Derneği Arşivi. 2013; 41(7): 633 - 637.
Vancouver GÜL İ,AYKAN A,GÖKDENİZ T,ÇELİK Ş A new hope in the treatment of coronary vasospasm: bosentan. Türk Kardiyoloji Derneği Arşivi. 2013; 41(7): 633 - 637.
IEEE GÜL İ,AYKAN A,GÖKDENİZ T,ÇELİK Ş "A new hope in the treatment of coronary vasospasm: bosentan." Türk Kardiyoloji Derneği Arşivi, 41, ss.633 - 637, 2013.
ISNAD GÜL, İlker vd. "A new hope in the treatment of coronary vasospasm: bosentan". Türk Kardiyoloji Derneği Arşivi 41/7 (2013), 633-637.